Company / Current Assets
Neurocrine Biosciences Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$2.5B
FY2025
5-year range
$972.8M / $2.5B
FY2021-FY2025
Trend
+46.3%
vs FY2024
Sector context
#29 of 215
Health Care
What the data says
Neurocrine Biosciences's current assets of $2.5B is higher than 87% of companies in the Health Care sector (FY2025). Current Assets has increased for 4 consecutive years, from $973M in FY2021 to $2.5B in FY2025.
Based on SEC 10-K filings.
$2.5B in FY2025 with a 5-year CAGR of +19.9%. Top quartile in the Health Care sector.
Improved from $1.6B to $2.5B over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +20.2%
- 5-Year CAGR
- +19.9%
- 10-Year CAGR
- -
Sector benchmark
In line with sector averageTop 13% of 215This company $2.5B Sector average $2.5B
▼
In line with sector average
Key checks
Key Insights
- Neurocrine Biosciences's current assets has grown for 4 consecutive years.
- 5-year CAGR of +19.9%, indicating consistent growth.
- In FY2025, current assets increased 46.3% year-over-year.
- Ranks #29 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5B | +46.3% |
| FY2024 | $1.7B | +7.3% |
| FY2023 | $1.6B | +10.6% |
| FY2022 | $1.5B | +49.4% |
| FY2021 | $972.8M | -4.3% |
| FY2020 | $1.0B | +22.3% |
| FY2019 | $831.0M | +12.6% |
| FY2018 | $737.8M | +33.0% |
| FY2017 | $554.9M | +78.8% |
| FY2016 | $310.4M | -19.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026